Managing Bone Density Loss

[Guest guest]

See: Israeli RS, et al, " Managing bone loss in men with locally

advanced prostate cancer receiving androgen deprivation therapy. " J

Urol. 2008 Feb;179(2):414-23.

" CONCLUSIONS: Because the most significant bone mineral density loss

occurs within year 1 of androgen deprivation therapy and most

fractures in healthy men occur in those without osteoporosis, early

intervention is warranted to prevent skeletal morbidity in patients

with nonmetastatic prostate cancer receiving androgen deprivation

therapy. Although the majority of and the most compelling evidence

supports the use of bisphosphonates for preventing and treating

androgen deprivation therapy induced bone loss, further study is

needed to define the optimal regimen, timing of initiation and

duration of therapy as well as long-term efficacy and safety. "

Pub Med ID: 18076933.

PubMed, a service of the US National Library of Medicine, is at

www.pubmed.gov

Regards,

Steve J